Biochemical Engineering Special Interest Group
biological engineering professionals
03 January 2017

Tiziana plots NASH combo after buying Novimmune asset

Tiziana Life Sciences has licensed an anti-interleukin-6 receptor (IL-6R) drug from Novimmune. The British biotech sees the monoclonal antibody as complementary to foralumab, a NASH candidate it picked up from Novimmune two years ago. Tiziana thinks the drug—NI-1201—can best rival products by binding to both membrane-bound and soluble IL-6R. Roche’s rheumatoid arthritis drug Actemra only binds to membrane-bound IL-6R. As importantly, Tiziana and its advisers think NI-1201 can unlock the potential of another of its pipeline prospects, anti-CD3 mAb foralumab. Source: Fierce Biotech 3/1/2017

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).